Implanet Stock

Implanet EBIT per Employee

The EBIT per Employee of Implanet (ALIMP.PA) as of Aug 4, 2026 is -150,545.45 EUR. In the previous year, EBIT per Employee was -145,363.64 EUR — a change of 3.56% (lower).

EBIT per Employee

-150,545.45EUR

YoY

3.56%

Last updated:

EBIT per Employee of Implanet is 2026 -150,545.45 EUR. EBIT per Employee of Implanet was 2025 -145,363.64 EUR. It decreases by 3.56% lower compared to the previous year.
Access this data via the Eulerpool API

Implanet Stock analysis

What does Implanet do? Implanet SA is a French company that specializes in the manufacture and distribution of innovative medical products. The company was founded in 2007 by Ludovic Lastennet and Rémi Boyer and is headquartered in Bordeaux, France. Implanet's business model focuses on the development, production, and marketing of medical implants and instruments to support orthopedic surgeries. The company works closely with leading surgeons and healthcare facilities to find the ideal solution for patient needs. One of Implanet's main areas of expertise is the spine. The company develops various implantable products for the treatment of degenerative diseases such as scoliosis. Another important area for Implanet is orthopedics, where the company develops solutions for joint problems like knee or hip replacements. The company also creates customized implants tailored to each individual patient for maximum accuracy and effectiveness. A key aspect of Implanet's business model is adapting its products to meet customer requirements. The company collaborates closely with its customers to meet their specific needs and deliver the best possible solution. Implanet is committed to developing innovative solutions that align with surgeons' capabilities and cater to their needs. Implanet maintains partnerships and distribution agreements worldwide to sell its products and achieve market gains. The company distributes its products in the US, Europe, and Asia. To further expand its presence in these markets, Implanet collaborates closely with healthcare organizations and surgeons to ensure its products remain up-to-date and meet customer needs. Implanet strives to develop innovative solutions that revolutionize orthopedics and spine care. The company has already achieved significant success in the past with its Jazz technology, which serves as an excellent example of how the company operates in a customer-oriented and innovative manner. The Jazz technology is an implant designed for scoliosis treatment and is customized to each individual patient. Overall, Implanet has developed an innovative and customer-oriented business model that focuses on continuous product development and collaboration with surgeons and healthcare organizations. With a strong presence in the global market and a range of innovative products, the company positions itself as one of the leading providers in the field of spine care and orthopedics. Implanet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Implanet stock

EBIT per Employee of Implanet is -150,545.45 EUR in 2026.

EBIT per Employee of Implanet changed from -145,363.64 EUR to -150,545.45 EUR, representing a 3.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Implanet since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Implanet historically and in real time.

Access this data via the Eulerpool API

Workforce — Implanet

All Key Metrics — Implanet